In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Biotech Is Specialty Pharma

Executive Summary

Europe's investment environment has forced much of the biotech sector to morph into specialty pharma. The situation isn't likely to change fast. Executives had best adapt, rather than complain.
Advertisement

Related Content

Europe's New Spec Pharma Models
Validating Europe's De-Risked Approach
Validating Europe's De-Risked Approach
Transatlantic M&A: The Only Way Out for European Biotechs?
Transatlantic M&A: The Only Way Out for European Biotechs?
In Endo, Vernalis Finds a Believer in Frova
In Endo, Vernalis Finds a Believer in Frova
Working Around Pre-Emption Rights
The US: To Go, or Not to Go?
Astex's Pyramid Scheme

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel